跳至主要内容
临床试验/NCT01857713
NCT01857713已完成不适用

A Multi-Center, Non-Randomized, Prospective Study of the Reza Band™ Upper Esophageal Sphincter (UES) Assist Device for the Treatment of Esophagopharyngeal Reflux

Somna Therapeutics, L.L.C.5 个研究点 分布在 1 个国家目标入组 95 人开始时间: 2013年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
95
试验地点
5
主要终点
Primary Safety

研究概览

简要总结

The purpose of the study is to determine the safety and effectiveness of non-invasive Reza Band UES Assist Device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing).

详细描述

The purpose of the study is to determine the safety and effectiveness of non-invasive Reza Band UES Assist Device for the treatment of esophagopharyngeal reflux with extra-esophageal symptoms (chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing). Reza Band is to be worn when sleeping. The patient will put the Reza Band on at bedtime and take it off upon waking.

This is a prospective, non-randomized, open label, multicenter study designed to assess the safety and effectiveness of the Reza Band. At up to 5 investigational sites, up to 100 subjects will be enrolled.

The primary effectiveness endpoint is to be evaluated by the Reflux Symptom Index (RSI). Success is defined as >25% reduction in the RSI at the last follow-up, as compared to the baseline RSI. The RSI is a validated nine-item patient-administered outcome questionnaire designed to document symptoms and severity. Patients are asked to rate how nine problems have affected them on a scale of 0 (no problem) to 5 (severe problem), with a maximum total score of 45.

All adverse reactions being reported will be evaluated with the frequency and percent of subjects of each reaction being summarized by severity and by relationship to the Reza Band. Since some subjects may report the same event several times (e.g., redness), the first occurrence of the worst reported case of the event will be used for the purpose of analysis.

The incidence of site reactions, including laryngospasm, choking, pain, cough and hoarseness will be summarized. Exact 95% confidence intervals for the incidence rate of site reactions will be presented.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •18 year of age or older
  • •The patient must be willing and able to provide informed consent.
  • •Understands the clinical study requirements and is able to comply with follow-up schedule.
  • •Clinically diagnosed with esophagopharyngeal reflux with extra-esophageal symptoms (i.e., chronic cough, choking, aspiration, chronic post nasal drip, globus, sore throat, throat clearing)
  • •Reflux Symptom Index (RSI) >13

排除标准

  • •Currently being treated with another investigational medical device and/or drug
  • •Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP)
  • •The patient is female and is of child bearing potential and is not using an acceptable method of birth control, or is pregnant or breast feeding.
  • •Previous head or neck surgery or radiation
  • •Carotid artery disease, thyroid disease, or history of cerebral vascular disease
  • •Suspected esophageal cancer
  • •Has either a pacemaker or implanted cardioverter defibrillator (ICD)
  • •Nasopharyngeal cancer
  • •Previously undergone Nissen Fundoplication

研究组 & 干预措施

Reza Band UES Assist Device

Active Comparator

Patient is own control. Compare baseline to last follow-up after using device

干预措施: Reza Band UES Assist Device (Device)

结局指标

主要结局

Primary Safety

时间窗: 4 Week Follow-up

Adverse reactions reported were evaluated with the frequency and percent of subjects of each reaction being summarized by severity and by relationship to the Reza Band UES Assist Device.

Percent Change in the Reflux Symptom Index (RSI) at 4 Weeks

时间窗: 4 Weeks minus Baseline

The RSI is a validated nine-item patient-administered outcome questionnaire designed to document symptoms and severity. Patients are asked to rate how nine problems have affected them on a scale of 0 (no problem) to 5 (severe problem), with a maximum total score of 45).

次要结局

  • SF-36 Short Form Health Survey - 4 Week Follow-up Score Compared to Baseline Score(4 Weeks minus Baseline)
  • Functional Outcomes of Sleep Questionnaire (FOSQ)(4 Weeks minus Baseline)

研究者

发起方
Somna Therapeutics, L.L.C.
申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验